By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Medivir AB 

Lunastigen 7

Huddinge    141 44  Sweden
Phone: 46-8-608-3100 Fax: 46-8-608-3199




GlaxoSmithKline (North Carolina) 

Peptimmune, Inc.  Development agreement for inhibitors of Cathepsin S for autoimmune and allergic diseases.

Company News
Medivir (MVRBF) Initiates Clinical Study Of Birinapant In Combination With KEYTRUDA (Pembrolizumab) In Patients With Treatment-Refractory Solid Tumours 8/18/2017 6:38:06 AM
Medivir (MVRBF) Licenses Exclusive Rights To MIV-802 For Greater China To Ascletis 8/18/2017 6:33:48 AM
FDA Accepts Medivir (MVRBF)'s IND Application For MIV-711, Enabling Clinical Development In The U.S. 8/16/2017 6:26:41 AM
Medivir (MVRBF) - Interim Report, January - June 2017 7/25/2017 11:24:11 AM
Medivir (MVRBF) Appoints John Öhd As Chief Medical Officer 6/19/2017 7:37:11 AM
Medivir (MVRBF) - Enrollment Completed In The MIV-711 Osteoarthritis Extension Study And Data Monitoring Committee Recommendation To "Go Ahead" 6/9/2017 6:36:19 AM
Medivir (MVRBF)'s CFO Will Leave His Position - Successor Recruitment Underway 5/30/2017 7:33:52 AM
Resolutions At The Annual General Meeting In Medivir (MVRBF) On 3 May 2017 5/3/2017 11:17:10 AM
Medivir (MVRBF) - Interim Report, January - March 2017 4/28/2017 10:18:53 AM
Medivir (MVRBF) Release: Update On The Development Of Simeprevir As Part Of The Triple Combination With AL-335 And Odalasvir (JNJ-4178) 4/24/2017 7:54:52 AM